Integrum: A neutral performance in Q3 - Redeye

Redeye returns with a more in-depth take of the Q3’21 report, which reflected a relatively neutral financial development. We have downed our sales estimates for the coming years due to a continuous uncertainty in elective surgery capacities and reconsiderations of contribution from the VA program in the shorter term – this poses a slight reassessment to our fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/835685/integrum-a-neutral-performance-in-q3?utm_source=finwire&utm_medium=RSS